Is Spravato (esketamine nasal spray) contraindicated in patients with a recent stroke (within the past 30 days)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Spravato (Esketamine) is Absolutely Contraindicated in Patients with Recent Stroke

Spravato is explicitly contraindicated in patients with a history of intracerebral hemorrhage, and should not be used in patients with recent ischemic stroke due to contraindications related to aneurysmal vascular disease and arteriovenous malformations 1.

FDA-Mandated Contraindications

The FDA drug label for Spravato clearly states the following absolute contraindications 1:

  • History of intracerebral hemorrhage (any prior hemorrhagic stroke)
  • Aneurysmal vascular disease (including intracranial vessels)
  • Arteriovenous malformation (including intracranial)

Clinical Reasoning for Stroke Patients

Hemorrhagic Stroke

Any patient with a history of intracerebral hemorrhage at any time point is permanently contraindicated from receiving Spravato. This is a black-and-white exclusion with no exceptions 1.

Recent Ischemic Stroke (Within 30 Days)

While the FDA label does not explicitly list "recent ischemic stroke" as a standalone contraindication, these patients should be considered contraindicated based on:

  1. Vascular instability: Acute stroke patients often have underlying aneurysmal disease or arteriovenous malformations that may not yet be diagnosed
  2. Blood pressure concerns: Spravato can cause significant hypertension 1, which is particularly dangerous in the acute stroke period (0-72 hours) when blood pressure management is critical and aggressive lowering can worsen outcomes 2, 3
  3. Risk of hemorrhagic transformation: Acute ischemic strokes carry risk of converting to hemorrhagic strokes, especially in the first 24-72 hours

Timing Considerations After Stroke

For ischemic stroke patients beyond the acute phase:

  • Before 3 months post-stroke: Exercise extreme caution. Obtain vascular imaging (CT angiography or MR angiography) to definitively rule out aneurysms or arteriovenous malformations before considering Spravato
  • After 3 months post-stroke: May consider if comprehensive vascular imaging is negative for contraindicated lesions and blood pressure is well-controlled

Critical Safety Monitoring Requirements

Even in patients without stroke history, Spravato requires 1:

  • Monitoring for at least 2 hours post-administration
  • Assessment of blood pressure changes
  • REMS program enrollment due to sedation and dissociation risks

Bottom Line Algorithm

Do NOT use Spravato if:

  • Any history of hemorrhagic stroke (permanent contraindication)
  • Ischemic stroke within past 3 months
  • Known intracranial aneurysm or arteriovenous malformation
  • Uncontrolled hypertension

May consider with extreme caution if:

  • Ischemic stroke >3 months ago AND
  • Negative vascular imaging for aneurysms/AVMs AND
  • Well-controlled blood pressure AND
  • Treatment-resistant depression with no other options

The risk-benefit calculation in stroke patients heavily favors avoiding Spravato due to the catastrophic consequences of intracranial hemorrhage versus the availability of alternative depression treatments.

References

Related Questions

What is the recommended dosing schedule, monitoring requirements, and contraindications for initiating Spravato (esketamine) nasal spray in an adult with treatment‑resistant major depressive disorder?
In a patient with a left ventricular ejection fraction of 30% and a history of seizures, is esketamine nasal spray (Spravato) an appropriate treatment option?
Is Spravato (esketamine nasal spray) safe or appropriate for a patient with a history of stroke and hepatitis?
How should a 10-year-old child presenting with cough and wheeze be evaluated and managed?
How should I evaluate and manage a patient with a blood pressure of 122/77 mm Hg and a heart rate of 123 beats per minute (tachycardia)?
In a post‑menopausal woman with hormone‑receptor‑positive, HER2‑positive metastatic breast cancer, should trastuzumab emtansine (T‑DM1) be given before or after fulvestrant?
How should a reproductive‑age woman with a shortened menstrual interval (cycles <21 days) be evaluated and managed?
What are the latest treatment options for human papillomavirus (HPV) infection and associated lesions?
What is the recommended management of ileus in a pediatric patient?
Can peripartum (post‑delivery) cardiomyopathy present as early as three to four days after childbirth?
Can antibiotics cause hyponatremia (low serum sodium)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.